Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada
- Appendino, Juan Pablo;
- Boelman, Cyrus;
- Brna, Paula M;
- Burneo, Jorge G;
- Claassen, Curtis S;
- Connolly, Mary B;
- De Guzman, Michael VT;
- Federico, Paolo;
- Floyd, Deirdre;
- Huntsman, Richard James;
- Javidan, Manouchehr;
- Jette, Nathalie;
- Jurasek, Laura L;
- Keezer, Mark R;
- Lau, Jonathan C;
- McCoy, Bláthnaid;
- McLachlan, Richard S;
- Ng, Marcus C;
- Nguyen, Dang Khoa;
- Reid, Aylin Y;
- Rho, Jong M;
- Snead, O Carter;
- Téllez-Zenteno, José F;
- Wang, Laura;
- Zak, Maria Martha
- et al.
Published Web Location
https://doi.org/10.1017/cjn.2019.282Abstract
In Canada, recreational use of cannabis was legalized in October 2018. This policy change along with recent publications evaluating the efficacy of cannabis for the medical treatment of epilepsy and media awareness about its use have increased the public interest about this agent. The Canadian League Against Epilepsy Medical Therapeutics Committee, along with a multidisciplinary group of experts and Canadian Epilepsy Alliance representatives, has developed a position statement about the use of medical cannabis for epilepsy. This article addresses the current Canadian legal framework, recent publications about its efficacy and safety profile, and our understanding of the clinical issues that should be considered when contemplating cannabis use for medical purposes.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.